Morbidity and cost of atopic eczema in Australia.

Morbidity and cost of atopic eczema in Australia. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Morbidity and cost of atopic eczema in Australia. Abstract Text:

Nicole Jenner,Jan Campbell,Robin Marks,Nicole Jenner,Jan Campbell,Robin Marks,

The severity, morbidity and financial costs of atopic eczema (AE) were assessed during a 1-year prospective study of a cohort of 85 people aged 14-63 years (mean 36 years) with the disease. A dermatologist examined each participant using the Six Area Six Sign Atopic Dermatitis severity scoring system to classify severity. Participants completed a Dermatology Life Quality Index (DLQI), a Nottingham Eczema Severity Score (NESS) and an ongoing diary of health-care consultations and treatment costs. Follow up by mail to each participant was conducted every 2 months and participants completed a NESS, a DLQI and a diary of costs incurred. The DLQI data revealed that 36% spent over 10 min per day applying treatments, 28% indicated that AE influenced the clothes they wore, 21% felt embarrassed by their skin and 15% reported problems with treatments. There appeared to be a relationship between increased morbidity and increased severity. The average annual out-of-pocket cost for products used for treatment was A$425, ranging from A$13.50 to over A$2000 per individual. The average out-of-pocket cost for medical consultations was A$120, ranging from zero to over A$800 per individual. Although there were concerns about the reproducibility of the severity and morbidity measures, the data showed that AE can have substantial effects both financially and from a personal perspective for those affected.

Morbidity and cost of atopic eczema in Australia. Publishing Authors By Initials

N Jenner,J Campbell,R Marks,N Jenner,J Campbell,R Marks,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Morbidity and cost of atopic eczema in Australia. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: The Australasian journal of dermatology

VOLUME: 45

Page Numbers: 16-22

Journal Abbreviation: Australas. J. Dermatol.

ISSN: 0004-8380

DAY: 13

MONTH: Feb

YEAR: 2004

Morbidity and cost of atopic eczema in Australia. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 135232

Morbidity and cost of atopic eczema in Australia. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Morbidity and cost of atopic eczema in Australia. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Morbidity and cost of atopic eczema in Australia.

AFFILIATION: University of Melbourne, Department of Medicine (Dermatology), St Vincent's Hospital Melbourne and Skin and Cancer Foundation of Victoria, Melbourne, Victoria, Australia.

Country: Australia

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Australas J Dermatol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Morbidity and cost of atopic eczema in Australia Related Publications

• 5alpha-reductase: history and clinical importance.
• A novel assay for monitoring internalization of nanocarrier coupled antibodies.
• Anxiety sensitivity and auditory perception of heartbeat.
• Cannabis laws: an analysis of costs.
• Continuous participation in voluntary groups as a protective factor for the psychological well-being of adults who develop functional limitations: evidence from the national survey of families and households.
• Darkness descends with two Rabs.
• Evaluation of expression based markers for the detection of breast cancer cells.
• Genetic diversity among Botulinum Neurotoxin-producing clostridial strains.
• Granulocyte transfusions in the G-CSF era. Where do we stand?
• Histone deacetylase inhibitors selectively suppress expression of HDAC7.
• Histone deacetylase inhibitors: molecular mechanisms of action.
• Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.
• Interrogational neuroimaging in counterterrorism: a "no-brainer" or a human rights hazard?
• MOSQUITOES (CULICIDAE) BITING A FISH (PERIOPHTHALMIDAE).
• Mechanisms of disease: Cytokine and adipokine signaling in uremic cachexia.
• Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin.
• Morbidity and cost of atopic eczema in Australia.
• One-pot terminal alkene homologation using a tandem olefin cross-metathesis/allylic carbonate reduction sequence.
• Penetrating spinal injury with wooden fragments causing cauda equina syndrome: case report and literature review.
• Predicting lung radiotherapy-induced pneumonitis using a model combining parametric Lyman probit with nonparametric decision trees.
• Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer.
• Regulation of central melanocortin signaling by interleukin-1 beta.
• Self-consistent tumor control probability and normal tissue complication probability models based on generalized EUD.
• Skin cancer: a practical guide to management.
• The impact of induction chemotherapy and the associated tumor response on subsequent radiation-related changes in lung function and tumor response.
• The role of functional imaging in the diagnosis and management of late normal tissue injury.
• The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum.
• The way of all flesh - the 21st Century.
• Updated assessment of the six-minute walk test as predictor of acute radiation-induced pneumonitis.
• Who really wants to save the apes?